Q-omics provides the consensus-scored B3GAT1-DT profile across patient tissues and cancer cell-line models. B3GAT1-DT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, B3GAT1-DT is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, B3GAT1-DT RNA expression shows 14,872 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where B3GAT1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GAT1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GAT1-DT survival associations across molecular data types. B3GAT1-DT RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GAT1-DT RNA expression–survival associations across cancer types. High B3GAT1-DT expression shows favorable associations in KIRP, UCEC, HNSC, KIRC, OV and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for B3GAT1-DT RNA expression.
This table summarizes B3GAT1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for B3GAT1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GAT1-DT shows lower tumor expression in KIRP, BRCA, KIRC and LUSC and higher tumor expression in THCA and KICH. The KIRP box plot shows higher B3GAT1-DT RNA expression in normal versus tumor tissue (log2 FC = −1.626, t-test p < 0.001).
This table shows molecular features associated with B3GAT1-DT in patient tissues and cancer cell lines. In patient samples, B3GAT1-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
